A Phase 1 interventional study of BMS-986177 in Thrombosis, sponsored by Bristol-Myers Squibb. Completed at 1 site in United States. Open to male participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-10-04.
Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Thrombosis by Bristol-Myers Squibb — none open to participants now, none under way, none of them phase 3. Thrombosis · Bristol-Myers Squibb.
Among the 19 studies in Thrombosis by Bristol-Myers Squibb, this one is the 18th largest by enrollment, is the only one that started in 2019, is one of 13 in phase 1, and was the 18th registered.
955 studies on the registry are indexed under Thrombosis; 171 are open to participants now.
Browse Thrombosis studies →None of the 19 studies in Thrombosis by Bristol-Myers Squibb is open now. The open studies under Thrombosis, anywhere →
Of the 126 Thrombosis studies recruiting now, 79 (63%) set no upper age limit and 16 (13%) stop at 75 or younger; 20 take children under 18; 20 take healthy volunteers.
This study: 18 Years to 50 Years · male · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 1 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 9 is below the median of 83 across 530 interventional studies indexed under Thrombosis.
Median enrollment 42 across the 19 interventional studies. Of the 19 that completed or were terminated, 7 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 19 studies in Thrombosis by Bristol-Myers Squibb, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is an ADME study. Human radiolabeled mass balance studies are performed as part of drug development to obtain information about the absorption, distribution, metabolism, and excretion (ADME) of a study treatment. The goals of human ADME studies include the assessment of absorption, distribution, routes and rates of excretion, mass balance, and metabolite profile and identification.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
On Day 1, all participants will receive a single oral solution dose of 200 mg \[14C\] BMS-986177 containing approximately 88 micro Ci of total radioactivity (TRA). Participants will remain in the clinical facility until at least Day 7 and will be discharged when release criteria are met or until Day 12
Drug: BMS-986177
On Day 1, all participants will receive a single oral solution dose of 200 mg \[14C\] BMS-986177 containing approximately 88 micro Ci of total radioactivity (TRA). Approximately 1 hour after study drug administration, an ND tube may be positioned in approximately 3 selected participants for collection of bile.Participants will remain in the clinical facility until at least Day 7 and will be discharged when release criteria are met or until Day 12
Drug: BMS-986177
An orally administered anticoagulant to prevent and treat thromboembolic events
Assess PK Cmax of a dose of [14C]BMS-986177
Cmax
Time frame: Day 1-12
Assess PK AUC(INF) of a dose of [14C]BMS-986177
AUC(INF)
Time frame: Day 1-12
Assess PK AUC(0-T) of a dose of [14C]BMS-986177
AUC(0-T)
Time frame: Day 1-12
Assess PK Tmax of a dose of [14C]BMS-986177
Tmax
Time frame: Day 1-12
Assess PK T-HALF of a dose of [14C]BMS-986177
T-HALF
Time frame: Day 1-12
Assess PK CL/F of a dose of [14C]BMS-986177
Time frame: Day 1-12
Assess PK Vz/F of a dose of [14C]BMS-986177
Vz/F
Time frame: Day 1-12
Assess PK AUC of a dose of [14C]BMS-986177
AUC(BMS-986177)
Time frame: Day 1-12
Assess PK AUC(TRA) of a dose of [14C]BMS-986177
AUC(TRA)
Time frame: Day 1-12
Assess PK Plasma AUC(TRA) of a dose of [14C]BMS-986177
Plasma AUC(TRA)
Time frame: Day 1-12
Assess PK Blood AUC(TRA) of a dose of [14C]BMS-986177
Blood AUC(TRA)
Time frame: Day 1-12
Assess the CLR of [14C]BMS-986177
CLR
Time frame: Day 1-12
Assess the %UR of [14C]BMS-986177
%UR
Time frame: Day 1-12
Assess the %FE of [14C]BMS-986177
%FE
Time frame: Day 1-12
Assess the %BE of [14C]BMS-986177
%BE (if applicable)
Time frame: Day 1-12
Assess the %Total recovery of [14C]BMS-986177
%Total recovery
Time frame: Day 1-12
Asess the Incidence of AEs of a single oral dose of 200 mg [14C] BMS-986177
Incidence of AEs
Time frame: Day 1-12
Asess the Incidence of SAEs of a single oral dose of 200 mg [14C] BMS-986177
Incidence of SAEs
Time frame: Day 1-12
Asess the Incidence of AEs leading to discontinuation of a single oral dose of 200 mg [14C] BMS-986177
Incidence of AEs leading to discontinuation
Time frame: Day 1-12
Assess the vital signs of a subject dosed with single oral dose of 200 mg [14C] BMS-986177
results of vital sign examination
Time frame: Day 1-12
Assess the ECGs of subjects dosed with single oral dose of 200 mg [14C] BMS-986177
ECG physical examinations
Time frame: Day 1-12
Assess the clinical lab tests of a single oral dose of 200 mg [14C] BMS-986177
Results of Clinical laboratory tests
Time frame: Day 1-12
Ran from May 2019 to primary completion in Jul 2019, 2 months.
Of 30 phase 1 interventional studies under Thrombosis, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 30. This study's 2 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Milvexian